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A B S T R A C T
The phytochemical sulforaphane can induce cell cycle arrest and apoptosis in metastatic prostate cancer
cells, though the mechanism of action is not fully known. We conducted a global proteome analysis in
LNCaP metastatic prostate cancer cells to characterize how global protein signature responds to
sulforaphane. We conducted parallel analyses to evaluate semi-quantitative 1-dimensional versus 2-
dimensional liquid chromatography tandem mass spectrometry (LC–MS/MS) and their utility in
characterizing whole cell lysate. We show that 2-dimensional LC–MS/MS can be a useful tool for
characterizing global protein proﬁles and identify TRIAP1 as a novel regulator of cell proliferation in
LNCaP metastatic prostate cancer cells.
Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
EuPA Open Proteomics
journal home page: www.elsevier .com/ locat e/euprot1. Introduction
Sulforaphane (1-isothiocyanato-4-(methylsulﬁnyl) butane) is a
plant derived isothiocyanate that can stimulate cell death in
metastatic prostate cancer cells while sparing normal prostate
epithelial cells under similar conditions [1]. Although this cytotoxic
effect has been known for some time, the underlying proteins and
signaling networks that control the response to sulforaphane are not
fully characterized. Characterizing the response to sulforaphane in
metastatic prostate cancer cells, and deﬁning the biological
signiﬁcance of observed responses, may therefore identify proteins
and/or pathways that confer cancer-selective cytotoxicity.
Sulforaphane stimulates a global change in gene transcription in
prostate cells that isbothdose-and time-dependent [2,3]. Analysis of
such global expression data has been used to infer the outcome of
sulforaphane treatment; however, there is reason to believe that this* Corresponding author at: School of Biological and Population Health Sciences,
103 Milam Hall, Oregon State University, Corvallis, OR 97331, United States.
Fax: +541 737 6914.
E-mail address: emily.ho@oregonstate.edu (E. Ho).
http://dx.doi.org/10.1016/j.euprot.2015.08.002
1876-3820/Published by Elsevier GmbH. This is an open access article under the CC BYtype of analysis fails to capture biologically relevant responses to
sulforaphane that govern proliferation and cell fate decisions. Gene
transcription is known to correlate poorly with protein level in
prostate cancercells [4], which can be a consequence of many factors
(e.g. protein stability, degradation rate, mutation, etc), suggesting
that drawing conclusions regarding phenotypic outcome based on
gene transcription alone may be misleading. Analysis of transcript
levels also cannot provide a full picture of immediate responses that
inﬂuence protein synthesis, stability or activity that is regulated
through control of translation or post-translational modiﬁcation [5].
This is particularly relevant with respect to sulforaphane since
previous research has noted a decrease in the mammalian target of
rapamycin (mTOR) activity, a master regulator of protein synthesis
[6,7], in response to sulforaphane that decreases global protein
synthesis in prostate cancer cells [8]. Furthermore, although some
changes in gene transcription may lead to rapid protein production,
others will take an extended time period to manifest at the protein
level. These observations suggest that transcript analyses cannot
provide a complete picture of the response to sulforaphane in
prostate cancer cells and that alternative methods that directly
assess protein levels will provide a clearer and more accurate
characterization of the factors that control cell fate following-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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characterize the protein proﬁle of LNCaP metastatic prostate cancer
cells and how it responds to sulforaphane.
Proteomic approaches have previously been applied to identify
sulforaphane-responsive proteins in several cell types [9–12],
though none have utilized an analysis of whole cell lysate to assess
the global proteome and how it responds to sulforaphane in
prostate cancer cells. We therefore subjected control- and
sulforaphane-treated LNCaP whole cell lysate to liquid-chroma-
tography tandem mass spectrometry (LC–MS/MS) for unbiased
assessment of potential alterations in global protein proﬁle. We
evaluated the standard protocol of peptide trapping and cleaning
upstream of 1-dimensional (1D) separation in parallel with 2-
dimensional (2D) reversed-phased (RP)/RP separation of lysate
prior to MS/MS analysis. 2D-RP/RP-LC–MS/MS has been shown to
increase proteome coverage relative to standard methods [13–18]
and could substantially increase our ability to detect changes in the
proteome in response to sulforaphane or identify proteins that
have not yet been implicated in prostate cancer cell biology. Two-
dimensional separation was found to be superior to standard 1D
methods in terms of proteome coverage and protein coverage.
Although we observed no global remodeling of the proteome in
response to sulforaphane under our experimental conditions,
increased proteome coverage by 2D separation methods did
identify biologically relevant proteins that inﬂuenced cancer cell
proliferation, suggesting 2D-RP/RP-LC–MS/MS may be a useful tool
for the discovery of novel protein targets for therapeutic
evaluation.
2. Materials and methods
2.1. Chemicals and reagents
Sulforaphane was purchased from LKT Laboratories (St. Paul,
MN, USA) and resuspended in dimethyl sulfoxide (DMSO) (EMD
Millipore, Darmstadt, Germany). Primary antibodies for TRIAP1
(Santa Cruz Biotechnology, Dallas, TX, USA), ﬁbrillarin (Santa Cruz
Biotechnology), p-S780-RB (Cell Signaling Technology, Danvers,
MA, USA), cyclin B1 (Cell Signaling), cyclin D2 (Santa Cruz
Biotechnology), p21 (Santa Cruz Biotechnology), NQO1 (Santa
Cruz Biotechnology), cleaved poly-ADP ribose polymerase (cPARP)
(Cell Signaling Technology), and GAPDH (Santa Cruz Biotechnolo-
gy) were used in accordance with the manufacturer’s protocol.
HRP-conjugated secondary antibodies (Santa Cruz Biotechnology)
for Western Blotting detection were used in accordance with the
manufacturer’s protocol. LC/MS grade solvents were purchased
form EMD MiIlipore (Billerica, MA, USA).
2.2. Cells and culture conditions
LNCaP metastatic prostate cancer cells were purchased from
American Type Culture Collection (ATCC, Manassas, VA, USA). Cells
were maintained in RPMI-1640 media with L-glutamine supple-
mented with fetal bovine serum (FBS, 50 ml FBS/500 ml media) at
37 C 5% CO2. Cell lines were validated by Idexx Radil (Columbia,
MO, USA) on December 24, 2012. Subconﬂuent cells were treated
under the indicated conditions prior to harvest. Sulforaphane was
used at 15 mM ﬁnal concentration. DMSO was used for control
treatments.
Sample preparation for LC/MS analysis:
LNCaP cells were treated for 24 h with DMSO (control) or
sulforaphane prior to harvest. Treatments were performed as
2 independent experiments. Cells were rinsed in 50 mM Tris–HCl
pH 7.8 and harvested in 0.5 M urea, 50 mM Tris–HCl pH 7.8, 5 mM
DTT. Lysate was heated at 95 C for 20 min then cleared of insoluble
material by centrifugation (10 min, 13,000 rpm, 4 C). Onemilligram protein per sample was digested overnight with
Trypsin-Gold in accordance with the manufacturer’s instructions
(Promega). Digestion was terminated with triﬂuoroacetic acid
(TFA). Protein digests were analyzed at the Mass Spectrometry
Core Facility at Oregon State University.
2.3. LC/MS analysis
Each sample was analyzed twice (two injections, technical
replicates) for downstream determination of treatment response.
Methods for 1D LC–MS/MS have been described previously [19].
Waters 2D nano acquity UPLC system (Waters Corp., Milford, MA,
USA) in “2D with dilution” conﬁguration was used for the 2-
dimentional analysis. System performance tests were conducted
according to the manufacturer protocol prior to the experiments.
Peptide sample solution (10 ml) was initially loaded onto a
XBridge300 (C18. 5 mm, 1.0  50 mm) reverse phase column using
20 mM ammonium formate (pH 10) with a ﬂow rate of 2 ml/min for
20 min. Peptide samples were then eluted from the high pH
trapping column and loaded onto the analytical trapping column
(Symmetry C18, 130 Å, 5 mm, 300 mm  50 mm) by using varying
concentration of acetonitrile (ACN) fractions (11.1, 14.5, 17.4, 20.8,
45 and 65%). Eluted peptides were diluted with 0.1% formic acid at
a ﬂow rate of 20 ml/min for 5 min. After this period, the column
valve was switched to allow the elution of peptides from the
trapping column onto the analytical column. Separation of
peptides was achieved by reverse-phase chromatography using
a C18 column (Agilent Zorbax 300SB-C18, 250  0.3 mm, 5 mm) at
ﬂow rate of 5 ml/min. Water and ACN with 0.1% formic acid were
used as solvent A and solvent B, respectively. The linear gradient
employed was 5–35% B in 45 min. Mass spectrometric analysis was
carried out in the same manner as the 1D analysis.
Raw data ﬁles were analyzed using Mascot and X!Tandem
database searching algorithms according to the protocol listed
previously [19]. Data comparison and quantiﬁcation was carried
out using Scaffold_3.3.1 (Proteome Software, Portland, OR, USA).
Peptide Prophet and Protein Prophet algorithms embedded in
Scaffold were used to calculate peptide and protein identiﬁcation
probabilities, respectively [20,21]. Scaffold uses spectral counting
for the data normalization. Spectra are summed across fractions for
each protein to acquire total spectra count (unweighted spectral
count). Sum of the “unweighted spectral count” are then scaled to
normalize across samples. The scaling factor for each sample is
then applied to each protein group and adjusts its “Unweighted
Spectrum Counts” to a normalized “Quantitative value”.
For variation analysis, MASCOT and X!Tandem peptide identi-
ﬁcation and protein assignment were analyzed as groups based on
technical replicates or treatment samples from the 2D dataset
(Supplemental data ﬁle). Spectra were summed across fractions for
each protein to acquire total spectra count. Sample #4 was omitted
from the technical variation analysis due to failure of Replicate #2.
The mean spectra count between technical replicates or treatment
samples was then calculated for each protein. Coefﬁcient of
variation (CV) for each protein was calculated based on standard
deviation and the calculated mean spectra count. X!Tandem
thresholds for this analysis: 5% false discovery rate (FDR) for
protein identiﬁcation, 5% FDR for peptide identiﬁcation, 2 peptide
minimum for positive protein identiﬁcation. Data was plotted and
analyzed using GraphPad Prism Software (La Jolla, CA, USA).
2.4. Protein preparation and western blot analysis
Protein lysates were prepared in RIPA protein lysis buffer
(150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholic acid
(NaDOC), 0.1% SDS, 20 mM TRIS pH 8.0) supplemented with
protease inhibitor cocktail (Thermo, Waltham, MA, USA). Lysates
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Protein Assay (BioRad, Hercules, CA, USA). Equal amounts of
protein were separated by SDS-PAGE and blotted to a PVDF
membrane (BioRad) using NuPAGE Reagents and equipment in
accordance with the manufacturer's protocol (Life Technologies).
Membranes were blocked and probed for the indicated proteins
following standard protocols. For protein detection, membranes
were incubated in SuperSignal West Femto Reagent (Thermo) and
developed on the AlphaInnotech FluorChem 8900 system (Pro-
teinSimple, San Jose, CA, USA). Densitometric analyses were
performed on the native membrane image using AlphaInnotech
FluorChem 8900 software (ProteinSimple). For each membrane,
the relative densitometric value of each replicate for a given probe
was normalized to the corresponding relative level of the
normalizing protein (ﬁbrillarin). For graphing, treatments are
expressed relative to control (set to the value 1).
2.5. TRIAP1 cloning
TRIAP1 was ampliﬁed from LNCaP cDNA prepared as
described previously [19] using the following primers: Sense 50
– TACTACTTAAGCTTATGAACAGTGTGGGGGAGGCATGCACGGACAT-
GAA – 30, Antisense 50 – TCTGAGAGCGGCCGCTTAATTAATTATCAA-
GAAGAATTTTCAGGCTTTTCTTTGCCATG – 30. The ampliﬁcation
product was cloned into a pCR2.1 TOPO TA cloning vector in
accordance with the manufacturer's protocol (Life Technologies).Fig. 1. Two-dimensional separation of whole cell lysate increases protein identiﬁcation a
harvest. Lysate was subjected to 1D and 2D LC–MS/MS analysis for assessment of cellular
group in LNCaP whole cell lysate. (B) Average coverage per protein identiﬁed in the analy
by treatment group of 2D coverage versus 1D coverage. Each point represents a uniquPlasmids were isolated using the PureLink Quick Plasmid Miniprep
Kit from Life Technologies and checked for TRIAP1 insert by PCR
ampliﬁcation (Sense: 50 – CGACCTCTTCAAGCGCTACC – 30, Anti-
sense: 50 – CCCATGAACTCCAGTCCTTCAA – 30). TRIAP1 coding
sequence was moved into a pCMV6-AC-GFP expression vector by
EcoRI digest and T4 DNA Ligase (Life Technologies) in accordance
with the manufacturer’s protocol (New England Biolabs, Ipswich,
MA, USA). Ligation products were transformed and grown in
TOP10 competent cells following the manufacturer's instructions
(Life Technologies). Plasmids were isolated as above and screened
for insert and directionality by PCR (TRIAP1 primers listed above
and VP1.5 primer). The correct construct was veriﬁed by assaying
protein expression following transient transfection in LNCaP cells.
2.6. Analysis of exogenous TRIAP1 in LNCaP cells
LNCaP cells were grown in 6-well plates and transfected with
pCMV6-AC-GFP or pCMV6-TRIAP1 with Lipofectamine 2000 in
accordance with the manufacturer’s protocol (Life Technologies).
Cells were placed under G418 selection (500 mg/ml) 24 h post-
transfection. Cells were taken off selection for 24 h after non-
transfected cells were eliminated (4–6 days) prior to beginning
treatments. After the indicated treatment period, cells were
harvested for protein analysis as described above.
For growth analysis, transfected LNCaP cells were prepared as
above. After elimination of non-transfected cells, G418 selectionnd coverage. LNCaP cells were treated with DMSO or sulforaphane for 24 h prior to
 proteins. (A) The number of proteins identiﬁed by 1D and 2D analysis by treatment
ses. 2D methods signiﬁcantly increased coverage per protein. (C and D) Scatter plots
e protein identiﬁed by both 1D and 2D method.
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seeded at 50,000 cells per well in 24-well plates for growth
analysis. At 24 h, media was replaced with selective media
(200 mg/ml G418). Cells from triplicate wells were treated with
trypsin, collected and counted at the indicated time-points on a
hemocytometer. Media was refreshed every other day.
2.7. Statistical analysis
Graphing and statistical analyses were performed using
GraphPad Prism Software. Figures depict one representative
experiment. Graphs depict mean + SEM for at least two indepen-
dent experiments. Statistical signiﬁcance was determined by
Student’s t-test. Signiﬁcance is indicated by asterisk, with * = p
< 0.05, ** = p < 0.01, *** = p < 0.001.
3. Results
3.1. 2-dimensional analysis improves protein identiﬁcation and
coverage in cell lysate
A signiﬁcant drawback to analysis of complex mixtures such as
whole cell lysate by LC–MS/MS using standard 1D separation
techniques is co-elution of parent peptides (i.e. low resolution).
One method to decrease the impact of this complication is to apply
2D separation techniques to complex peptide mixtures prior to
MS/MS analyses. We therefore applied 2-dimensional separationFig. 2. Sulforaphane does not alter global protein proﬁle in LNCaP cells. Data from 2D ana
(mean spectra count [m]) for data separated by technical replicates (open circles) and tre
of residuals (Technical Replicates: Y = 0.6694 X +0.1427; Treatment Samples: Y = 0.597
function of log (mean spectra count [m]) for the chart in (A). (C) Box plot of residuals bas
proteins identiﬁed by 2D analysis that were unique to each group (Technical versus Tre
separated by group (Technical versus Treatment) (whiskers 5-95 percentile). (For interpr
web version of this article.)reverse-phase (RP)/RP LC–MS/MS to tryptic digests of LNCaP
metastatic prostate cancer cells to assess potential changes in
protein proﬁle and identify candidate biologically relevant proteins
that may have a role in the cellular response to sulforaphane
(Fig. 1). Two-dimensional analyses signiﬁcantly increased the
number of high-conﬁdence proteins identiﬁed in LNCaP whole cell
lysate compared to 1D analysis (Fig. 1A): 244 proteins versus 117
(DMSO) and 219 versus 121 (SF). Increasing separation also
signiﬁcantly increased the coverage of proteins identiﬁed (Fig. 1B–
D). Two-dimensional analyses increased percent coverage by an
average of 44% in proteins identiﬁed in both 1D and 2D analyses.
3.2. Sulforaphane does not alter global protein proﬁle in LNCaP cells
To test whether sulforaphane stimulates a rapid response in the
cellular proteome in metastatic prostate cancer cells, LNCaP cells
were exposed to DMSO (control) or 15 mM sulforaphane for 24 h
and then processed for proteomic analyses. A 15 mM treatment was
chosen because this plasma concentration has been shown to slow
prostate cancer in vivo [22,23]. Treatments were carried out as two
biological replicates, and each replicate was analyzed as two
technical replicates (two injections) for downstream analysis and
signal determination. To assess whether sulforaphane stimulates a
change in the relative level of proteins identiﬁed in both control-
and sulforaphane-treated LNCaP cells, coefﬁcient of variation (CV)
was plotted against mean spectra count for data analyzed as
technical replicate samples (open circles) or as treatment sampleslysis was analyzed for changes in global protein proﬁle. (A) log (CV [s/m]) versus log
atment samples (red triangles). A line was ﬁt to each group for downstream analysis
0 X +0.08734). (B) Residual plot for Technical Replicates and Treatment Samples as a
ed on group (Technical versus Treatment) (whiskers 1-99 percentile). (D) Percent of
atment). (E) Box plot of spectra count for unique proteins identiﬁed in the analysis
etation of the references to colour in this ﬁgure legend, the reader is referred to the
Fig. 3. Sulforaphane inﬂuences TRIAP1 protein level in LNCaP cells. (A)
Representative blot of TRIAP1 protein at 24 h and 48 h after sulforaphane treatment.
The nuclear protein ﬁbrillarin was probed as a loading control. (B) Sulforaphane
causes a transient decrease in TRIAP1 protein in LNCaP cells. Graph represents
2 independent experiments (mean + SEM).
Fig. 4. TRIAP1 inﬂuences cell proliferation in LNCaP cells. (A) Growth curve of
LNCaP cells expressing exogenous TRIAP1 or GFP (control). Cells were counted at 48,
72 and 96 h post-seeding. (B) LNCaP cells expressing exogenous TRIAP1 or GFP
(control) were treated with DMSO (control) or sulforaphane for 48 h and analyzed
for the indicated proteins. p-S780-RB, cyclin B1, cyclin D2 and p21 were analyzed to
assess the inﬂuence of TRIAP1 and sulforaphane on cell cycle regulators. NQO1 was
analyzed as a marker for sulforaphane response. The nuclear protein ﬁbrillarin was
probed as a loading control. Blots are representative of 2 independent experiments.
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between treatment samples will indicate high variability in protein
level and a potential sulforaphane effect. As seen in the log
transformed plot in Fig. 2A, log CV decreases as log mean spectra
count increases. A residual plot of deviation from a line ﬁt to each
group for each data point in Fig. 2A showed that variation between
treatment samples is consistent with technical variation, suggest-
ing no treatment effect (Fig. 2B). A box plot of residuals for
technical replicates and treatment samples also did not indicate
speciﬁc proteins deviate from what is technical variation (Fig. 2C).
The above analysis is appropriate for assessing relative changes
in protein levels, but could miss rapid induction or degradation
between treatments. An analysis for proteins unique to one
technical replicate or one treatment group was therefore
conducted (Fig. 2D). The percent of unique proteins between
treatment groups was lower than what was observed between
technical replicates (31.1% versus 40.9%, respectively) (Fig. 2D). A
box plot of spectra count for unique proteins identiﬁed in technical
replicates and treatment samples also suggested that sulforaphane
does not lead to rapid protein induction/degradation at the global
level (Fig. 2E). Proteins with a spectra count under 4 in our analysis
dominated the population of unique protein identiﬁcations,
suggesting that identiﬁcation of low-spectra count proteins may
be largely stochastic.
3.3. Identiﬁcation of TRIAP1 in LNCaP cells
Although sulforaphane did not lead to a rapid shift in protein
proﬁle at a global level, the phytochemical is known to stimulate
induction, modiﬁcation or degradation of discrete proteins [24].
We therefore manually analyzed the proteins identiﬁed by 2D
analysis for high-conﬁdence proteins that may be involved in the
cellular response to sulforaphane. Global analyses identiﬁed
proteins involved in a wide array of cellular processes (Supple-
mental data ﬁle). We narrowed our focus to proteins involved in
cell proliferation and/or apoptosis since we are interested in using
increased proteome coverage to identify novel proteins that may
respond to sulforaphane and have a role in these processes in
metastatic prostate cancer cells. TP53-regulated inhibitor of
apoptosis 1 (TRIAP1; p53CSV) was identiﬁed in sulforaphane-
treated LNCaP lysate and has not previously been reported as a
sulforaphane-responsive protein. TRIAP1 is regulated by p53, an
key transcription factor in stress response, cell fate and apoptosis,
and sulforaphane is known to stimulate a p53 response in LNCaP
cells [25–28]. We therefore focused our analyses on determining
whether TRIAP1 responds to sulforaphane and whether TRIAP1 has
a role in LNCaP cell-maintenance. Sulforaphane treatment led to a
transient decrease in TRIAP1, though the effect did not reach
statistical signiﬁcance (Fig. 3A).
3.4. TRIAP1 inﬂuences proliferation rate in LNCaP cells
TRIAP1 has not previously been reported as a sulforaphane-
responsive protein and the consequences of altered expression
levels in metastatic prostate cancer cells are not known. To
understand what role TRIAP1 may play in LNCaP cells and in the
response to sulforaphane, we provided exogenous TRIAP1 and then
treated cells with sulforaphane or DMSO (control).
Exogenous TRIAP1 decreased proliferation in LNCaP cells
(Fig. 4A). Despite slowing proliferation rate, increased
TRIAP1 levels did not signiﬁcantly alter the protein level of select
cell-cycle regulators relative to GFP-control (Fig. 4B). We observed
no inﬂuence on the level of phospho-Retinoblastoma (p-S780-RB),
cyclin B1, cyclin D2 or p21. TRIAP1 also did not signiﬁcantly
inﬂuence the cellular response to sulforaphane in LNCaP cells;
sulforaphane led to decreased cyclin levels, increased p21 andincreased NQO1 protein levels and was not dependent on
TRIAP1 levels (Fig. 4B). An assessment of cleaved-polyADP-ribose
polymerase (cPARP) also suggested that TRIAP1 does not impair
mitochondrial integrity or sensitize LNCaP cells to sulforaphane
(Fig. S2).
4. Discussion
In this investigation we utilized an unbiased 2D LC–MS/MS
approach to characterize potential changes in the cellular
proteome in LNCaP metastatic prostate cancer cells following
sulforaphane treatment. Characterizing the proteome and
G.W. Watson et al. / EuPA Open Proteomics 9 (2015) 34–40 39potential changes in response to sulforaphane can provide a broad
view of the proteins and processes that may mediate the cancer-
cytotoxic effects associated with sulforaphane as well as identify
new proteins that inﬂuence LNCaP cell growth/survival and may be
evaluated as potential novel therapeutic targets.
Sulforaphane is known to stimulate global changes in gene
expression and has been shown to enhance protein degradation
through the proteasome in some cell types, including metastatic
prostate cancer cells [2,3,9,19,29–33]. This suggests a remodeling
of the cellular proteome following exposure. However, we did not
identify any change in global protein signature following
sulforaphane treatment in LNCaP cells (Fig. 2). This is supported
by our recent ﬁndings that sulforaphane does not lead to a global
change in lysosomal degradation or ubiquitinated protein levels in
LNCaP cells (Watson et al., in press). This suggests that although
sulforaphane can modulate the expression of many genes, from a
global view, the proteome is relatively stable. This is not to suggest
that sulforaphane does not inﬂuence the level of discrete proteins.
In our molecular analysis we did conﬁrm well characterized
changes in speciﬁc cell cycle regulators and cytoprotective
enzymes (Fig. 4). Our global view likely missed these proteins
for several reasons. Although 2D analysis is superior to 1D analysis
(Fig. 1), it may still lack sufﬁcient resolution to identify low-
abundance proteins or proteins that have been transcriptionally
activated but have not accumulated to a high enough level to be
detected. Increasing the number of fractions per sample may
provide further improvements in detecting lower-abundance
proteins. In addition, other techniques such as data-independent
acquisition and SWATH-MS [34] may be better suited to identify
lower-abundance proteins in complex whole cell lysate and could
be worth exploring in future work. Despite these limitations,
expanding proteome coverage by 2D LC–MS/MS did identify many
proteins for assessment for biological relevance in LNCaP
proliferation and/or survival (Fig. 1).
TRIAP1 was identiﬁed in our 2D LC–MS/MS analysis and has not
previously been characterized in LNCaP cells. TRIAP1 expression is
controlled by p53, and sulforaphane is known to induce a cell
stress response that leads to p53 stabilization and activation in
LNCaP cells [25–27]. This suggests that TRIAP1 may be a
downstream mediator of the p53 response in LNCaP cells.
TRIAP1 has been reported as having a role in cell cycle regulation
in several cancer cell lines, though its role is cell-line-dependent.
The protein is reported to directly inﬂuence p21 protein levels and
therefore inﬂuence cell cycle arrest and apoptosis [35]. TRIAP1 has
also been reported to have a more direct role in apoptosis through
maintaining mitochondrial integrity [36]. We found that sulfo-
raphane led to a transient decrease of TRIAP1 in LNCaP cells (Fig. 3),
suggesting a potential role in inﬂuencing cell growth and survival.
To assess any role for TRIAP1 in cell proliferation we provided
exogenous TRIAP1 in LNCaP cells and then monitored cell cycle
regulators and growth (Fig. 4). TRIAP1 did not signiﬁcantly inﬂuence
p21 levels, indicating TRIAP1 does not directly regulate p21 in LNCaP
cells. Exogenous TRIAP1 also did not inﬂuence other selected cell
cycle regulators (Fig. 4B) or basal apoptotic signaling as assessed by
cPARP (Fig. S2). Having discovered no direct inﬂuence on previously
characterized TRIAP1 processes in LNCaP cells, we assessed a
potential role for inﬂuencing the response to sulforaphane (Fig. 4B
and Fig. S2). Sulforaphane led to similar decreases in p-S780-RB,
cyclin B1 and cyclin D2, and similar induction in p21 and
NQO1 regardless of TRIAP1 level. Increased TRIAP1 also did not
inﬂuence apoptotic signaling in response to sulforaphane in LNCaP
cells (Fig. S2). Although TRIAP1 did not inﬂuence select proteins
involved in cell cycle regulation, exogenous expression did
signiﬁcantly decrease cell proliferation (Fig. 4A) and is consistent
with it being a downstream effector of p53. Further work will beneeded to understand how TRIAP1 leads to decreased growth and
will be an interesting area of future research.
5. Conclusion
2D-RP/RP-LC–MS/MS is a useful tool for analyzing global
protein proﬁle in an unbiased manner from whole cell lysate.
This method provided greater coverage of the global proteome and
also increased the coverage of discrete proteins relative to standard
methods. Enhanced proteome coverage by 2D methods can be used
to identify previously unreported proteins that inﬂuence cell
behavior in metastatic prostate cancer cells and thus identify new
potential targets for therapeutic development.
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